Hematogenix's Mm Mrd Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's Zenbexus™, the First Approved CELMoD Therapy for Multiple Myeloma PR Newswire (Press Release) 13:40 Wed, 19 Aug
Zenbexus Granted Accelerated Approval in Relapsed or Refractory Multiple Myeloma Hematology Advisor 15:35 Mon, 17 Aug
Hematogenix's Proprietary MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma PRWeb (Press Release) 23:30 Fri, 14 Aug
BMS Targets Community Setting With Zenbexus, Its First Approved CELMoD Scrip Pharma Intelligence 21:34 Fri, 14 Aug
BMS bags first FDA approval for CELMoD franchise with Zenbexus multiple myeloma nod FiercePharma 15:18 Fri, 14 Aug
BMS secures FDA accelerated approval for Zenbexus in multiple myeloma Pharmaceutical Business Review 10:44 Fri, 14 Aug
SFDA becomes first regulatory authority globally to approve registration of 'ZENBEXUS' to treat multiple myeloma in adults Saudi Gazette 22:24 Tue, 11 Aug
